Andre Rogatko

Title(s)Adjunct Professor, Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    São Paulo University, São Paulo, BrazilB.S.12/1976Biological Sciences
    São Paulo University, São Paulo, BrazilM.S.12/1978Genetics/Statistics
    São Paulo University, São Paulo, BrazilPh.D.12/1983Genetics/Statistics

    Collapse Overview 
    Collapse Overview
    The research of Andre Rogatko, PhD, focuses on using statistical methods to improve the design and analysis of clinical trials, genetic epidemiology, and risk prediction.

    Collapse Research 
    Collapse Research Activities and Funding
    The NIH SPAN Coordinating Center
    NIH U24NS113452Aug 1, 2019 - Jul 31, 2022
    Role: Co-Investigator
    Women's Ischemia Syndrome Evaluation (WISE) - Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)
    NIH R01HL146158May 1, 2019 - Feb 29, 2024
    Role: Co-Investigator
    Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials
    NIH U01CA232859Sep 19, 2018 - Aug 31, 2023
    Role: Principal Investigator
    A Multicenter RCT of Pharmacist-Directed Transitional Care to Reduce Post-Hospitalization Utilization
    NIH R01AG058911Sep 1, 2018 - Jun 30, 2023
    Role: Co-Investigator
    A blood test to identify prostate cancer patients at risk for visceral metastasis
    NIH R01CA218356Jun 19, 2017 - May 31, 2022
    Role: Co-Investigator
    UCLA Clinical Translational Science Institute
    NIH UL1TR001881Jul 1, 2016 - May 31, 2022
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. Mol Cancer Ther. 2022 01; 21(1):217-226. Osada T, Crosby EJ, Kaneko K, Snyder JC, Ginzel JD, Acharya CR, Yang XY, Polascik TJ, Spasojevic I, Nelson RC, Hobeika A, Hartman ZC, Neckers LM, Rogatko A, Hughes PF, Huang J, Morse MA, Haystead T, Lyerly HK, Osada T, Crosby EJ, Kaneko K, Snyder JC, Ginzel JD, Acharya CR, Yang XY, Polascik TJ, Spasojevic I, Nelson RC, Hobeika A, Hartman ZC, Neckers LM, Rogatko A, Hughes PF, Huang J, Morse MA, Haystead T, Lyerly HK. PMID: 34675120; PMCID: PMC8742774.
      View in: PubMed   Mentions:    Fields:    
    2. Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer-Specific Quality of Life Questionnaire. Clin Ther. 2021 07; 43(7):1245-1252. Hays RD, Ganz PA, Spritzer KL, Rogatko A. PMID: 34183169.
      View in: PubMed   Mentions:    Fields:    
    3. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One. 2021; 16(6):e0252665. Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B, Rimel BJ. PMID: 34081738; PMCID: PMC8174738.
      View in: PubMed   Mentions:    Fields:    
    4. Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. Am Heart J. 2021 07; 237:90-103. Handberg EM, Merz CNB, Cooper-Dehoff RM, Wei J, Conlon M, Lo MC, Boden W, Frayne SM, Villines T, Spertus JA, Weintraub W, O'Malley P, Chaitman B, Shaw LJ, Budoff M, Rogatko A, Pepine CJ. PMID: 33745898.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 06 10; 39(17):1865-1877. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS. PMID: 33449816; PMCID: PMC8260909.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    6. On the properties of the toxicity index and its statistical efficiency. Stat Med. 2021 03 15; 40(6):1535-1552. Razaee ZS, Amini AA, Diniz MA, Tighiouart M, Yothers G, Rogatko A. PMID: 33345351; PMCID: PMC7953898.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. J Natl Cancer Inst. 2020 12 14; 112(12):1266-1274. Gresham G, Diniz MA, Razaee ZS, Luu M, Kim S, Hays RD, Piantadosi S, Tighiouart M, Yothers G, Ganz PA, Rogatko A. PMID: 32091598; PMCID: PMC7735773.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. Clin Cancer Res. 2019 05 01; 25(9):2725-2736. Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop T, Kim S, Rogatko A, Lubkov V, Snyder JC, Osada T, Hobeika AC, Morse MA, Lyerly HK, Hartman ZC. PMID: 30635338; PMCID: PMC6497539.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    9. Comparison between continuous and discrete doses for model based designs in cancer dose finding. PLoS One. 2019; 14(1):e0210139. Diniz MA, Tighiouart M, Rogatko A. PMID: 30625194; PMCID: PMC6326565.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Improving admission medication reconciliation with pharmacists or pharmacy technicians in the emergency department: a randomised controlled trial. BMJ Qual Saf. 2018 07; 27(7):512-520. Pevnick JM, Nguyen C, Jackevicius CA, Palmer KA, Shane R, Cook-Wiens G, Rogatko A, Bear M, Rosen O, Seki D, Doyle B, Desai A, Bell DS. PMID: 28986515; PMCID: PMC5912995.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    11. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat. 2018; 28(3):562-574. Tighiouart M, Cook-Wiens G, Rogatko A. PMID: 28858566; PMCID: PMC5832533.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Critical evaluation of the Hirschsprung-associated enterocolitis (HAEC) score: A multicenter study of 116 children with Hirschsprung disease. J Pediatr Surg. 2018 Apr; 53(4):708-717. Frykman PK, Kim S, Wester T, Nordenskjöld A, Kawaguchi A, Hui TT, Teitelbaum DH, Granström AL, Rogatko A, HAEC Collaborative Research Group (HCRG). PMID: 28760457; PMCID: PMC6247908.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    13. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials. Am J Biostat. 2016; 6(1):1-11. Tighiouart M, Li Q, Piantadosi S, Rogatko A. PMID: 28706582; PMCID: PMC5505662.
      View in: PubMed   Mentions: 4  
    14. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials. Stat Med. 2017 01 30; 36(2):280-290. Tighiouart M, Li Q, Rogatko A. PMID: 27060889; PMCID: PMC5055414.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    15. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016 05 14; 37(19):1504-13. Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, Thomson LE, Berman DS, Shaw LJ, Petersen JW, Brown GH, Anderson RD, Shuster JJ, Cook-Wiens G, Rogatko A, Pepine CJ. PMID: 26614823; PMCID: PMC4872284.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    16. Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding. Entropy (Basel). 2015 Aug; 17(8):5288-5303. Rogatko A, Cook-Wiens G, Tighiouart M, Piantadosi S. PMID: 27156869; PMCID: PMC4859761.
      View in: PubMed   Mentions: 3  
    17. Combined Quantitative Assessment of Myocardial Perfusion and Coronary Artery Calcium Score by Hybrid 82Rb PET/CT Improves Detection of Coronary Artery Disease. J Nucl Med. 2015 Sep; 56(9):1345-50. Brodov Y, Gransar H, Dey D, Shalev A, Germano G, Friedman JD, Hayes SW, Thomson LE, Rogatko A, Berman DS, Slomka PJ. PMID: 26159582.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    18. A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Apr 15; 21(8):1859-68. Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR. PMID: 25673697; PMCID: PMC4401630.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    19. Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes. Am J Cardiol. 2015 Apr 15; 115(8):1073-9. Zhang X, Li Q, Rogatko A, Tighiouart M, Hardison RM, Brooks MM, Kelsey SF, Kaul S, Bairey Merz CN. PMID: 25724784; PMCID: PMC4380580.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene. 2015 May 21; 34(21):2690-9. Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW. PMID: 25065597.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansAnimalsCells
    21. miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 2014 Sep 01; 20(17):4636-46. Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW. PMID: 24963047; PMCID: PMC4155061.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    22. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control. Stat Med. 2014 Sep 28; 33(22):3815-29. Tighiouart M, Piantadosi S, Rogatko A. PMID: 24825779; PMCID: PMC4156522.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    23. Escalation with overdose control using time to toxicity for cancer phase I clinical trials. PLoS One. 2014; 9(3):e93070. Tighiouart M, Liu Y, Rogatko A. PMID: 24663812; PMCID: PMC3963973.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    24. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer. 2014 Apr; 21(2):311-26. Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J, Freeman MR, Chung LW. PMID: 24478054; PMCID: PMC3959765.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    25. Transferring inpatient rehabilitation facility cancer patients back to acute care (TRIPBAC). PM R. 2014 Sep; 6(9):808-13. Asher A, Roberts PS, Bresee C, Zabel G, Riggs RV, Rogatko A. PMID: 24440553.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    26. Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One. 2013; 8(9):e73081. Hu P, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, Zhau HE. PMID: 24066029; PMCID: PMC3774681.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    27. Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS One. 2013; 8(7):e68366. Josson S, Matsuoka Y, Gururajan M, Nomura T, Huang WC, Yang X, Lin JT, Bridgman R, Chu CY, Johnstone PA, Zayzafoon M, Hu P, Zhau H, Berel D, Rogatko A, Chung LW. PMID: 23874600; PMCID: PMC3707913.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    28. The Integrated Web Portal for Escalation with Overdose Control (EWOC). Open Med Inform J. 2013; 7:18-23. Wang H, Tighiouart M, Huang SC, Berel D, Cook-Wiens G, Bresee C, Li Q, Rogatko A. PMID: 23847696; PMCID: PMC3706802.
      View in: PubMed   Mentions: 1  
    29. Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation. J Pediatr Hematol Oncol. 2013 May; 35(4):e149-52. Qayed M, Langston A, Chiang KY, August K, Hilinski JA, Cole CR, Rogatko A, Bostick RM, Horan JT. PMID: 23274384.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    30. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. Br J Cancer. 2013 Mar 05; 108(4):762-5. Harvey RD, Owonikoko TK, Lewis CM, Akintayo A, Chen Z, Tighiouart M, Ramalingam SS, Fanucchi MP, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS. PMID: 23322195; PMCID: PMC3590658.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    31. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2011 Feb; 34(1):70-5. Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. PMID: 20458210; PMCID: PMC3030655.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    32. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol. 2011 Feb; 35(2):161-76. Nese N, Martignoni G, Fletcher CD, Gupta R, Pan CC, Kim H, Ro JY, Hwang IS, Sato K, Bonetti F, Pea M, Amin MB, Hes O, Svec A, Kida M, Vankalakunti M, Berel D, Rogatko A, Gown AM, Amin MB. PMID: 21263237.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    33. caGrid-Enabled caBIG Silver Level Compatible Head and Neck Cancer Tissue Database System. Open Med Inform J. 2010 Sep 01; 4:171-8. Wang H, Bouzyk E, Kuehn A, Muller S, Chen Z, Khuri FR, Shin DM, Rogatko A, Tighiouart M. PMID: 21589853; PMCID: PMC3095113.
      View in: PubMed   Mentions:
    34. Is the updated Schwartz formula appropriate for assessing renal function prior to hematopoietic stem cell transplantation? Pediatr Blood Cancer. 2010 Jul 15; 55(1):199-201. Qayed M, Thompson A, Applegate K, Haight A, Rogatko A, Chiang KY, Horan J. PMID: 20486187.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Sep 01; 27(25):4116-23. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. PMID: 19636016; PMCID: PMC2734423.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    36. Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate. 2009 Jan 01; 69(1):1-11. Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, Rogatko A, Osunkoya AO, Zayzafoon M, Chung L, Petros JA. PMID: 18850577; PMCID: PMC2753601.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    37. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008 Aug; 37(2):154-8. Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD. PMID: 18665076.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    38. Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol. 2008 May 20; 26(15):2464-72. Parker KP, Bliwise DL, Ribeiro M, Jain SR, Vena CI, Kohles-Baker MK, Rogatko A, Xu Z, Harris WB. PMID: 18487566.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    39. Translation of innovative designs into phase I trials. J Clin Oncol. 2007 Nov 01; 25(31):4982-6. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. PMID: 17971597.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    40. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007 Apr 01; 67(5):1389-93. Freedman GM, Meropol NJ, Sigurdson ER, Hoffman J, Callahan E, Price R, Cheng J, Cohen S, Lewis N, Watkins-Bruner D, Rogatko A, Konski A. PMID: 17394942.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    41. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Jul; 6(2):125-32. Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ. PMID: 16945168.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    42. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res. 2005 Aug 01; 11(15):5342-6. Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. PMID: 16061846.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    43. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005 Aug 01; 104(3):561-9. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. PMID: 16028213.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    44. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med. 2005 Jul 30; 24(14):2183-96. Tighiouart M, Rogatko A, Babb JS. PMID: 15909291.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    45. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005 Jul; 5(2):108-13. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. PMID: 16098251.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    46. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 01; 11(3):1226-36. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. PMID: 15709193.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    47. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma. Haematologica. 2004 Dec; 89(12):1484-91. Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. PMID: 15590399.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    48. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer. 2004 Nov 01; 101(9):2034-41. Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR. PMID: 15455357.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    49. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res. 2004 Jul 15; 10(14):4645-51. Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR. PMID: 15269136.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    50. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol. 2004 Feb 15; 22(4):602-9. Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. PMID: 14966084.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    51. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Jun; 53(6):513-8. Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ. PMID: 14760509.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    52. Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplant. 2004 Jan; 33(1):71-8. Lewis NL, Mullaney M, Mangan KF, Klumpp T, Rogatko A, Broccoli D. PMID: 14704659.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    53. Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas. Sarcoma. 2004; 8(4):107-11. von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT, Rogatko A. PMID: 18521404; PMCID: PMC2395616.
      View in: PubMed   Mentions: 9  
    54. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003 Dec; 44(12):2000-18. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM. PMID: 14660727.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    55. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol. 2003 Oct; 10(8):910-5. Brown T, Sigurdson E, Rogatko A, Broccoli D. PMID: 14527910.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    56. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr 01; 21(7):1301-6. Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. PMID: 12663718.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    57. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res. 2003 Jan; 9(1):109-14. Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. PMID: 12538458.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    58. Hardy-Weinberg equilibrium diagnostics. Theor Popul Biol. 2002 Nov; 62(3):251-7. Rogatko A, Slifker MJ, Babb JS. PMID: 12408944.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    59. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002 Aug 15; 62(16):4767-72. Cheng JD, Dunbrack RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. PMID: 12183436.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    60. Patient specific dosing in a cancer phase I clinical trial. Stat Med. 2001 Jul 30; 20(14):2079-90. Babb JS, Rogatko A. PMID: 11439422.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    61. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001 Jul; 58(1):59-64. Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. PMID: 11445480.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    62. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2001 May; 7(5):1181-91. von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. PMID: 11350882.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCellsCTClinical Trials
    63. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001 Apr; 8(3):260-7. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. PMID: 11314944.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    64. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol. 2001 Feb 15; 19(4):1183-94. Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF. PMID: 11181685.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    65. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res. 2000 Jun; 6(6):2219-28. von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM. PMID: 10873071.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    66. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung. Lung Cancer. 2000 Jan; 27(1):37-45. Schilder RJ, Goldberg M, Millenson MM, Movsas B, Rogatko A, Rogers B, Langer CJ. PMID: 10672782.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    67. Allelic instability as a predictor of survival in Egyptian breast cancer patients. Int J Oncol. 1999 Oct; 15(4):757-67. Zekri AR, Bahnassi AA, Bove B, Huang Y, Russo IH, Rogatko A, Shaarawy S, Shawki OA, Hamza MR, Omer S, Khaled HM, Russo J. PMID: 10493959.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    68. Exploring family relationships in cancer risk counseling using the genogram. Cancer Epidemiol Biomarkers Prev. 1999 Apr; 8(4 Pt 2):393-8. Daly M, Farmer J, Harrop-Stein C, Montgomery S, Itzen M, Costalas JW, Rogatko A, Miller S, Balshem A, Gillespie D. PMID: 10207645.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    69. Constructing meiotic maps with known error probability. Genet Epidemiol. 1999; 16(3):274-89. Rogatko A, Babb J, Jordan H, Zacks S. PMID: 10096690.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998 May 30; 17(10):1103-20. Babb J, Rogatko A, Zacks S. PMID: 9618772.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    71. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997 Oct-Nov; 4(7):551-6. Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. PMID: 9367020.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    72. Utility of linked markers in genetic counseling: estimation of carrier risks in X-linked ocular albinism. Am J Med Genet. 1997 May 02; 70(1):58-66. Rebbeck TR, Jordan HA, Schnur RE, Rogatko A. PMID: 9129743.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    73. Evaluation of genotype data in clinical risk assessment: methods and application to BRCA1, BRCA2, and N-acetyl transferase-2 genotypes in breast cancer. Genet Test. 1997-1998; 1(3):157-64. Rebbeck TR, Rogatko A, Viana MA. PMID: 10464641.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Phase II studies: which is worse, false positive or false negative? J Natl Cancer Inst. 1996 Apr 03; 88(7):462. Rogatko A, Litwin S. PMID: 8618240.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res. 1996 Mar; 2(3):549-52. Obasaju CK, Johnson SW, Rogatko A, Kilpatrick D, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ, Gallo JM. PMID: 9816202.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    76. Risk prediction with linked markers: pedigree analysis. Am J Med Genet. 1995 Oct 23; 59(1):24-32. Rogatko A, Rebbeck T, Zacks S. PMID: 8849005.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    77. Risk prediction with linked markers: theory. Am J Med Genet. 1995 Oct 23; 59(1):14-23. Rogatko A. PMID: 8849004.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 1995; 35(3):205-12. Hageboutros A, Rogatko A, Newman EM, McAleer C, Brennan J, LaCreta FP, Hudes GR, Ozols RF, O'Dwyer PJ. PMID: 7805178.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    79. Loss of blood group antigen A in non-small cell lung cancer. Ann Surg Oncol. 1994 Sep; 1(5):423-7. Gwin JL, Klein-Szanto AJ, Zhang SY, Agarwal P, Rogatko A, Keller SM. PMID: 7850544.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    80. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. 1994 Feb 01; 54(3):709-17. Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D, et al. PMID: 8306332.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    81. Ordering genes: controlling the decision-error probabilities. Am J Hum Genet. 1993 May; 52(5):947-57. Rogatko A, Zacks S. PMID: 8488844; PMCID: PMC1682055.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Mutagens, N-nitroso compounds and their precursors in gastric juice from patients with and without precancerous lesions of the stomach. Eur J Cancer. 1993; 29A(14):2031-9. Pignatelli B, Malaveille C, Rogatko A, Hautefeuille A, Thuillier P, Muñoz N, Moulinier B, Berger F, De Montclos H, Lambert R, et al. PMID: 8280498.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    83. Esmolol infusion during nitroprusside-induced hypotension: impact on hemodynamics, ventricular performance, and venous admixture. J Cardiothorac Vasc Anesth. 1992 Apr; 6(2):196-200. Shah N, Del Valle O, Edmondson R, Acampora G, Dwyer D, Matarazzo D, Rogatko A, Thorne A, Bedford RF. PMID: 1348963.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    84. Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery. 1992 Mar; 111(3):301-10. Pisters PW, Cersosimo E, Rogatko A, Brennan MF. PMID: 1542855.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    85. Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol. 1992 Mar; 147(3):601-5. Klein EA, Rogatko A, Herr HW. PMID: 1538437.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    86. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg. 1991 Nov; 214(5):627-36. Coit DG, Rogatko A, Brennan MF. PMID: 1953117; PMCID: PMC1358620.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    87. The hemodynamic response to hemorrhage in tumor-bearing animals. Surgery. 1991 Sep; 110(3):508-13. Younes RN, Rogatko A, Brennan MF. PMID: 1887374.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    88. Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br J Surg. 1991 Sep; 78(9):1053-8. de Rooij PD, Rogatko A, Brennan MF. PMID: 1718529.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    89. The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg. 1991 Aug; 214(2):107-13. Younes RN, Rogatko A, Brennan MF. PMID: 1867517; PMCID: PMC1358508.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    90. The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. 1991 Apr; 109(4):459-67. Cersosimo E, Pisters PW, Pesola G, Rogatko A, Vydelingum NA, Bajorunas D, Brennan MF. PMID: 2008651.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    91. Effects of hypovolemia and transfusion on tumor growth in MCA-tumor-bearing rats. Surgery. 1991 Mar; 109(3 Pt 1):307-12. Younes RN, Rogatko A, Vydelingum NA, Brennan MF. PMID: 2000562.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    92. Effect of splenectomy on morbidity and survival following curative gastrectomy for carcinoma. Arch Surg. 1991 Mar; 126(3):359-64. Brady MS, Rogatko A, Dent LL, Shiu MH. PMID: 1998479.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    93. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. Arch Surg. 1991 Mar; 126(3):328-34. Bevilacqua RG, Rogatko A, Hajdu SI, Brennan MF. PMID: 1998475.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    94. Prognosis of pregnancy-associated breast cancer. Cancer. 1991 Feb 15; 67(4):869-72. Petrek JA, Dukoff R, Rogatko A. PMID: 1991259.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    95. Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival. Eur Urol. 1991; 19(2):97-100. Herr HW, Klein EA, Rogatko A. PMID: 2022226.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    96. Cardiopulmonary resuscitation and the patient with cancer. J Clin Oncol. 1991 Jan; 9(1):111-5. Vitelli CE, Cooper K, Rogatko A, Brennan MF. PMID: 1985159.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    97. Axillary dissection in melanoma. Prognostic variables in node-positive patients. Ann Surg. 1990 Aug; 212(2):125-31. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. PMID: 2375645; PMCID: PMC1358045.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    98. Axillary lymphadenectomy. A prospective, randomized trial of 13 factors influencing drainage, including early or delayed arm mobilization. Arch Surg. 1990 Mar; 125(3):378-82. Petrek JA, Peters MM, Nori S, Knauer C, Kinne DW, Rogatko A. PMID: 2407228.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    99. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med. 1989 Mar 23; 320(12):773-7. Sheinfeld J, Schaeffer AJ, Cordon-Cardo C, Rogatko A, Fair WR. PMID: 2922027.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    100. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989 Feb; 73(2):391-6. Auerbach AD, Rogatko A, Schroeder-Kurth TM. PMID: 2917181.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    101. Statistical inference in the gene order problem: theoretical aspects. Prog Clin Biol Res. 1989; 329:63-8. Rogatko A, Zacks S. PMID: 2622964.
      View in: PubMed   Mentions: 1     Fields:    
    Andre's Networks
    Concepts (542)
    Derived automatically from this person's publications.
    Co-Authors (18)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department